Washington, the District Of Columbia-based Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services. The company is valued at $142.3 billion by market cap. The leading global life sciences and diagnostics innovator is expected to announce its fiscal second-quarter earnings for 2025before the market opens on Tuesday, Jul. 22.

Ahead of the event, analysts expect DHR to report a profit of $1.64 per share on a diluted basis, down 4.7% from $1.72 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion. 

For the full year, analysts expect DHR to report EPS of $7.70, up 2.9% from $7.48 in fiscal 2024. Its EPS is expected to rise 11.4% year over year to $8.58 in fiscal 2026. 

DHR stock has underperformed the S&P 500 Index’s ($SPX) 13.6% gains over the past 52 weeks, with shares down 20.9% during this period. Similarly, it underperformed the Health Care Select Sector SPDR Fund’s (XLV) 7.5% dip over the same time frame.

On Apr. 22, DHR shares closed up more than 3% after reporting its Q1 results. Its adjusted EPS of $1.88 surpassed Wall Street expectations of $1.62. The company’s revenue was $5.7 billion, topping Wall Street forecasts of $5.6 billion. DHR expects full-year adjusted EPS in the range of $7.60 to $7.75.

Analysts’ consensus opinion on DHR stock is bullish, with a “Strong Buy” rating overall. Out of 23 analysts covering the stock, 18 advise a “Strong Buy” rating, one suggests a “Moderate Buy,” and four give a “Hold.” DHR’s average analyst price target is $243, indicating a potential upside of 23% from the current levels.